AstraZeneca PLC $AZN Holdings Increased by Yousif Capital Management LLC

Yousif Capital Management LLC grew its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 9.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 33,778 shares of the company’s stock after buying an additional 2,780 shares during the quarter. Yousif Capital Management LLC’s holdings in AstraZeneca were worth $2,360,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AZN. CWM LLC grew its stake in shares of AstraZeneca by 88.1% in the 2nd quarter. CWM LLC now owns 18,973 shares of the company’s stock worth $1,326,000 after purchasing an additional 8,886 shares during the last quarter. Vanguard Personalized Indexing Management LLC grew its stake in shares of AstraZeneca by 7.1% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 123,529 shares of the company’s stock worth $8,636,000 after purchasing an additional 8,192 shares during the last quarter. Oak Ridge Investments LLC grew its stake in shares of AstraZeneca by 1.0% in the 2nd quarter. Oak Ridge Investments LLC now owns 91,644 shares of the company’s stock worth $6,404,000 after purchasing an additional 912 shares during the last quarter. Concurrent Investment Advisors LLC grew its stake in shares of AstraZeneca by 13.5% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 36,442 shares of the company’s stock worth $2,547,000 after purchasing an additional 4,328 shares during the last quarter. Finally, Richardson Financial Services Inc. grew its stake in shares of AstraZeneca by 59.8% in the 2nd quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock worth $28,000 after purchasing an additional 149 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently issued reports on AZN. Weiss Ratings reaffirmed a “buy (b)” rating on shares of AstraZeneca in a research note on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft cut shares of AstraZeneca from a “hold” rating to a “sell” rating in a research note on Thursday. Finally, Berenberg Bank set a $97.00 price objective on shares of AstraZeneca in a research note on Wednesday, July 9th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, AstraZeneca has an average rating of “Moderate Buy” and an average target price of $86.00.

AstraZeneca Stock Performance

AstraZeneca stock opened at $84.69 on Friday. The firm’s 50 day simple moving average is $80.23 and its 200-day simple moving average is $73.85. The company has a market cap of $262.66 billion, a P/E ratio of 31.84, a price-to-earnings-growth ratio of 1.54 and a beta of 0.36. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.67. AstraZeneca PLC has a fifty-two week low of $61.24 and a fifty-two week high of $86.57.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Tuesday, July 29th. The company reported $1.09 earnings per share for the quarter, hitting the consensus estimate of $1.09. The business had revenue of $14.46 billion for the quarter, compared to the consensus estimate of $14.08 billion. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The firm’s quarterly revenue was up 16.1% compared to the same quarter last year. During the same period last year, the firm posted $1.24 earnings per share. As a group, equities research analysts predict that AstraZeneca PLC will post 4.51 EPS for the current year.

AstraZeneca Cuts Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Monday, September 8th. Investors of record on Friday, August 8th were given a dividend of $0.505 per share. The ex-dividend date of this dividend was Friday, August 8th. This represents a yield of 200.0%. AstraZeneca’s payout ratio is presently 37.97%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.